Daniel Modin1, Brian Claggett2, Lars Køber3,4, Morten Schou5,3, Jens Ulrik Stæhr Jensen3,6, Scott D Solomon2, Orly Vardeny7, Filip Krag Knop3,8, Susanne Dam Nielsen3,9, Michael Fralick10, Christian Torp-Pedersen11, Gunnar Gislason5,3, Tor Biering-Sørensen5,12. 1. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark danielmodin.md@gmail.com. 2. Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 4. Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 5. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 6. Respiratory Medicine Section, Department of Internal Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 7. Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, and University of Minnesota, Minneapolis, MN. 8. Center for Clinical Metabolic Research, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 9. Department of Infectious Disease, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 10. Sinai Health System and Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 11. Department of Health Science and Technology, Aalborg University, and Departments of Cardiology and Epidemiology/Biostatistics, Aalborg University, Aalborg, Denmark. 12. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: Recent influenza infection is associated with an increased risk of atherothrombotic events, including acute myocardial infarction (AMI) and stroke. Little is known about the association between influenza vaccination and cardiovascular outcomes in patients with diabetes. RESEARCH DESIGN AND METHODS: We used nationwide register data to identify patients with diabetes in Denmark during nine consecutive influenza seasons in the period 2007-2016. Diabetes was defined as use of glucose-lowering medication. Patients who were not 18-100 years old or had ischemic heart disease, heart failure, chronic obstructive lung disease, cancer, or cerebrovascular disease were excluded. Patient exposure to influenza vaccination was assessed before each influenza season. We considered the outcomes of death from all causes, death from cardiovascular causes, and death from AMI or stroke. For each season, patients were monitored from December 1 until April 1 the next year. RESULTS: A total of 241,551 patients were monitored for a median of four seasons (interquartile range two to eight seasons) for a total follow-up of 425,318 person-years. The vaccine coverage during study seasons ranged from 24% to 36%. During follow-up, 8,207 patients died of all causes (3.4%), 4,127 patients died of cardiovascular causes (1.7%), and 1,439 patients died of AMI/stroke (0.6%). After adjustment for confounders, vaccination was significantly associated with reduced risks of all-cause death (hazard ratio [HR] 0.83, P < 0.001), cardiovascular death (HR 0.84, P < 0.001), and death from AMI or stroke (HR 0.85, P = 0.028) and a reduced risk of being admitted to hospital with acute complications associated with diabetes (diabetic ketoacidosis, hypoglycemia, or coma) (HR 0.89, P = 0.006). CONCLUSIONS: In patients with diabetes, influenza vaccination was associated with a reduced risk of all-cause death, cardiovascular death, and death from AMI or stroke. Influenza vaccination may improve outcome in patients with diabetes.
OBJECTIVE: Recent influenza infection is associated with an increased risk of atherothrombotic events, including acute myocardial infarction (AMI) and stroke. Little is known about the association between influenza vaccination and cardiovascular outcomes in patients with diabetes. RESEARCH DESIGN AND METHODS: We used nationwide register data to identify patients with diabetes in Denmark during nine consecutive influenza seasons in the period 2007-2016. Diabetes was defined as use of glucose-lowering medication. Patients who were not 18-100 years old or had ischemic heart disease, heart failure, chronic obstructive lung disease, cancer, or cerebrovascular disease were excluded. Patient exposure to influenza vaccination was assessed before each influenza season. We considered the outcomes of death from all causes, death from cardiovascular causes, and death from AMI or stroke. For each season, patients were monitored from December 1 until April 1 the next year. RESULTS: A total of 241,551 patients were monitored for a median of four seasons (interquartile range two to eight seasons) for a total follow-up of 425,318 person-years. The vaccine coverage during study seasons ranged from 24% to 36%. During follow-up, 8,207 patients died of all causes (3.4%), 4,127 patients died of cardiovascular causes (1.7%), and 1,439 patients died of AMI/stroke (0.6%). After adjustment for confounders, vaccination was significantly associated with reduced risks of all-cause death (hazard ratio [HR] 0.83, P < 0.001), cardiovascular death (HR 0.84, P < 0.001), and death from AMI or stroke (HR 0.85, P = 0.028) and a reduced risk of being admitted to hospital with acute complications associated with diabetes (diabetic ketoacidosis, hypoglycemia, or coma) (HR 0.89, P = 0.006). CONCLUSIONS: In patients with diabetes, influenza vaccination was associated with a reduced risk of all-cause death, cardiovascular death, and death from AMI or stroke. Influenza vaccination may improve outcome in patients with diabetes.
Authors: Ricardo Lopez Santi; Daniel Leonardo Piskorz; Manlio F Marquez; Cristhian Ramirez Ramos; Nicolás Federico Renna; Martin Ibarrola; Fernando Stuardo Wyss; Adrián Naranjo Dominguez; Gonzalo Emanuel Perez; Juan María Farina; Ezequiel Forte; Jorge Paul Juarez Lloclla; Emma Flores de Espinal; Adriana Puente Barragan; Mauro Gabriel Ruise; Diego Delgado; Adrian Baranchuk Journal: CJC Open Date: 2020-08-28
Authors: Jose J Zamorano-Leon; Rodrigo Jimenez-Garcia; Ana Lopez-de-Andres; Javier de-Miguel-Diez; David Carabantes-Alarcon; Romana Albaladejo-Vicente; Rosa Villanueva-Orbaiz; Khaoula Zekri-Nechar; Sara Sanz-Rojo Journal: J Clin Med Date: 2021-12-23 Impact factor: 4.241
Authors: Salah T Al Awaidy; Fatima Al Slail; Dalal Abdul Aziz Al Kathiry; Zayid K Al Mayahi; Parvaiz A Koul; Mine Durusu Tanriover Journal: Oman Med J Date: 2021-11-30
Authors: Guilherme S Lopes; Sheila M Manemann; Susan A Weston; Ruoxiang Jiang; Nicholas B Larson; Ethan D Moser; Véronique L Roger; Paul Y Takahashi; Yader Sandoval; Malcolm R Bell; Alanna M Chamberlain; LaPrincess C Brewer; Mandeep Singh; Jennifer L St Sauver; Suzette J Bielinski Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-12-13